Cargando…

Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan

BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hase, Ryota, Suzuki, Daisuke, de Luise, Cynthia, Chen, Haoqian, Nonnenmacher, Edward, Higuchi, Takakazu, Katayama, Kayoko, Kinjo, Mitsuyo, Jinno, Sadao, Morishima, Toshitaka, Sugiyama, Naonobu, Tanaka, Yoshiya, Setoguchi, Soko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548573/
https://www.ncbi.nlm.nih.gov/pubmed/37789253
http://dx.doi.org/10.1186/s12879-023-08466-8
_version_ 1785115296742244352
author Hase, Ryota
Suzuki, Daisuke
de Luise, Cynthia
Chen, Haoqian
Nonnenmacher, Edward
Higuchi, Takakazu
Katayama, Kayoko
Kinjo, Mitsuyo
Jinno, Sadao
Morishima, Toshitaka
Sugiyama, Naonobu
Tanaka, Yoshiya
Setoguchi, Soko
author_facet Hase, Ryota
Suzuki, Daisuke
de Luise, Cynthia
Chen, Haoqian
Nonnenmacher, Edward
Higuchi, Takakazu
Katayama, Kayoko
Kinjo, Mitsuyo
Jinno, Sadao
Morishima, Toshitaka
Sugiyama, Naonobu
Tanaka, Yoshiya
Setoguchi, Soko
author_sort Hase, Ryota
collection PubMed
description BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases. RESULTS: Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM. CONCLUSIONS: VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08466-8.
format Online
Article
Text
id pubmed-10548573
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105485732023-10-05 Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan Hase, Ryota Suzuki, Daisuke de Luise, Cynthia Chen, Haoqian Nonnenmacher, Edward Higuchi, Takakazu Katayama, Kayoko Kinjo, Mitsuyo Jinno, Sadao Morishima, Toshitaka Sugiyama, Naonobu Tanaka, Yoshiya Setoguchi, Soko BMC Infect Dis Research BACKGROUND: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). METHODS: VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases. RESULTS: Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM. CONCLUSIONS: VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08466-8. BioMed Central 2023-10-03 /pmc/articles/PMC10548573/ /pubmed/37789253 http://dx.doi.org/10.1186/s12879-023-08466-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hase, Ryota
Suzuki, Daisuke
de Luise, Cynthia
Chen, Haoqian
Nonnenmacher, Edward
Higuchi, Takakazu
Katayama, Kayoko
Kinjo, Mitsuyo
Jinno, Sadao
Morishima, Toshitaka
Sugiyama, Naonobu
Tanaka, Yoshiya
Setoguchi, Soko
Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title_full Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title_fullStr Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title_full_unstemmed Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title_short Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
title_sort validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in japan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548573/
https://www.ncbi.nlm.nih.gov/pubmed/37789253
http://dx.doi.org/10.1186/s12879-023-08466-8
work_keys_str_mv AT haseryota validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT suzukidaisuke validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT deluisecynthia validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT chenhaoqian validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT nonnenmacheredward validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT higuchitakakazu validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT katayamakayoko validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT kinjomitsuyo validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT jinnosadao validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT morishimatoshitaka validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT sugiyamanaonobu validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT tanakayoshiya validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan
AT setoguchisoko validityofclaimsbaseddiagnosesforinfectiousdiseasescommonamongimmunocompromisedpatientsinjapan